Daily Stock Opinions and Ratings

Opinions

The Panic-Proof Portfolio (Stockchase Research)Gilead Sciences Inc.GILDTOP PICKOct 27, 2020

Stockchase Research Editor: Michael O'Reilly As the first developer of COVID-19 treatment with its remdesivir (approved by the FDA). The product will be sold under the name of Veklury for patients that need hospitalization. This follows recent new treatments, one for breast cancer and another for HIV. Although the drugs are expensive, they have been proven to be effective in their treatment. We would buy this with a stop-loss at $50. Yield 4.53% (Analysts’ price target is $78.65)

The Panic-Proof Portfolio (Stockchase Research)

Unknown

Unlock Rating

$60.02

Stock price when the opinion was issued

$124.30

As of Jun 15, 2026. Market Open.

biotechnologypharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

DON'T BUY

He had owned it for 10 years at a time when it had a blockbuster drug that cured hepatitis. Gilead took profits and invested them into HIV drugs. As with other drug companies holding patents on blockbuster drugs with expiry dates, don't buy this one.

BUY

He waited a long time to see performance, but patience paid off. Earnings are accelerating, fueled by their HIV platform.

WATCH

Hitting 52-week highs. Caught his attention because last week they beat top and bottom lines. After consolidating 9 years, it's starting to break out. Doesn't know this well enough to see if this breakout will hold, but worth watching.

PARTIAL SELL

The business isn't worth as much as the stock is selling, even though shares have recently bounced back.

DON'T BUY

High flyer because of Hep C, so successful it isn't needed on an ongoing basis. Its HIV drug was equally successful. Ironically, success impacted growth of those drugs negatively. Decent dividend.

BUY

Healthcare is down 2% year. He likes the devices in HC, with Stryker his top pick. Surgeries are coming back, and the company has a new suite of products coming.

BUY

Was upgraded today

It's a biopharma which as a group did very well last year. Compare that to the smaller biotechs which have not done well the past 3 years. This year, biopharma and staples have underperformed. This boasts a high free cash flow yield and has a great product cycle coming.

HOLD

Chart pattern indicating weakness in the company.
Risk lower than the past year.
$60 share price a good time to buy.

WATCH

In past years, biotech was the safe trade, but this year risk is back, so these stocks have fallen out of favour. Also, there are so many drugs in trials now and big pharma needs new product. She's looking at Gilead and Moderna, because they have low PEs and alot of drugs in development. However, the overall sector is risky.

BUY

Has long owned this, because it's a value stock and keeps raising its dividend.

WAIT

It is a biotech company well known for a cure for Hepatitis C which is off patent now. It made several acquisitions and has built out an HIV franchise. He needs to see execution on the oncology platform and elsewhere.

DON'T BUY

No new drugs or trials. Doing nothing interesting. Prefers Eli Lilly.

BUY

It was upgraded today. What an earnings report, and they increased full-year guidance. Their HIV franchise continues to drive the top and bottom lines. Long-term, they continue to expand in oncolocy treatments--their pipeline looks fine.

BUY

Likes healthcare. This pays a 4.5% dividend yield, because of the strength of their drugs. Likes their huge pipeline of drugs, spanning cell therapy, oncology and HIV. They just beat top and bottom lines and raised their 2022 guidance.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Oct 27/20, Up 6.6%)Stockchase Research Editor: Michael O’Reilly Our PAST TOP PICK with GILD has triggered its stop at $64. To remain disciplined, we recommend covering the position at this time. We will look for better opportunities.

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Richard Orrell

RN Croft Financial Group

Stockchase Insights

5i Research